Gossamer Bio, Inc.
GOSSHealthcare|Biotechnology|US
$9.77
+0.35 (+3.72%)
DCF Value
$117.58
Cash / Share
$20.66
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Stock Price
-94.7%(1Y)
1M
-1.1%
3M
-31.4%
6M
-62.7%
YTD
-96.1%
1Y
-95.1%
3Y
-79.5%
5Y
-99.1%
Pipeline Summary
13 total trials5
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
Completed: 7Terminated: 4Recruiting: 1Suspended: 1
Active Trials (1)
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
Phase 3Recruiting
Enrollment: 330 participants
Key Facts
Market Cap$59.7M
Employees161 (+12% YoY)
CEOFaheem Hasnain
IPO DateFeb 8, 2019
Beta2.00
52-Week Range$8.29 – $309.6
Avg Volume329,918
ExchangeNASDAQ
Websitegossamerbio.com
Ownership
Float26.3%
Shares Outstanding6.1M
Recent Insider Trades
Milligan SandraAWARD
Sep 23, 202610,000 shares @ $10.99
Daniel Thomas OAWARD
Sep 23, 202610,000 shares @ $10.99
Ciongoli Gregory AustinAWARD
Sep 23, 202630,000 shares @ $10.99
Drynan SkyeAWARD
Sep 23, 202610,000 shares @ $10.99
Quisel John DAWARD
Sep 23, 202610,000 shares @ $10.99
Peers
Recent News
Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS
Sep 28, 2026 · defenseworld.net
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Sep 23, 2026 · businesswire.com
Hsbc Holdings PLC Increases Stock Position in Gossamer Bio, Inc. $GOSS
Sep 17, 2026 · defenseworld.net
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Sep 16, 2026 · businesswire.com
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Sep 11, 2026 · gurufocus.com
Data last updated: Nov 9, 2026, 04:12 AM